Is uniQure N.V. (QURE) a Buy, Sell, or Hold?
NASDAQ : QURE
uniQure N.V.
$43.2708 USD
$1.08 (2.56%)
- Volume
- 1.02M
- Average Volume
- 2.18M
- Market Capitalization
- $3B
- P/E Ratio
- -10.72
- Dividend Yield
- 0.00%
- Price Target
- $60.50
- Year High
- $71.50
- Year Low
- $8.73
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.01
Company Overview
NASDAQ
Matthew Kapusta
Biotechnology
Healthcare
QURE
221
NL
USD
Liquidity Metrics
0.19
10.01
10.01
4.96
0.00
Sales & Valuation
$16.1M
160.95
8.86
-18.66
-2.43
Profitability
-$3.46
-$198.97M
-1350.73%
-1313.04%
-111.96%
-25.60%
P/E Metrics
-10.72
1.01
1.01
Analyst Price Target & Rating
$60.50
$80.00
$28.00
1/5
38 Analysts
-28.48%
Financial Health Scores
0.75
3/9
$750.92M
$985.1M
$661.05M
-$177.74M
Key Metrics (TTM)
$2.52B
134.92
-15.43
10.01
-111.96%
-22.00%
-9.02%
-5.61%
-148 days
Company Executives
| Name | Title |
|---|---|
| Richard Porter | Chief Business & Scientific Officer |
| Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary |
| Chiara Elizabeth Russo | Senior Director of Investor Relations |
| Walid Abi-Saab | Chief Medical Officer |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site |
| Amin Abujoub | Chief Technical Operations Officer |
| Tamara Tugal | Business Development Director |
| Matthew Craig Kapusta | Chief Executive Officer & Executive Director |
| Erin Boyer | Chief People & Culture Officer |
| Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Kylie O'Keefe | Chief Customer & Strategy Officer |
Poll Results
No votes yet today — be the first to share your view!
About uniQure N.V. (NASDAQ:QURE) Stock
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement wi ... th Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
2026-07-30 12:01:11
uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.
2026-07-30 08:05:16
Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy stocks.
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
2026-07-29 14:53:19
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
uniQure Q2 Earnings Call Highlights
2026-07-29 13:05:39
uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track to submit a biologics license application in the third quarter of 2026.
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
2026-07-29 09:31:08
uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.69 per share a year ago.
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
2026-07-29 07:05:00
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~ ~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~ ~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130 and continued pipeline investment ~ ~ uniQure to host earnings call at 8:30 a.m. ET ~ LEXINGTON, Mass.
uniQure to Announce Second Quarter 2026 Financial Results
2026-07-22 07:05:00
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
2026-07-17 15:56:04
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
Frequently Asked Questions
-
What is the current uniQure N.V. (QURE) stock price?
-
uniQure N.V.(NASDAQ:QURE) stock price is $43.2708 in the last trading session. During the trading session, QURE stock reached the peak price of $71.5 while $8.73 was the lowest point it dropped to. The percentage change in QURE stock occurred in the recent session was 2.56% while the dollar amount for the price change in QURE stock was $1.08.
-
QURE's industry and sector of operation?
-
The NASDAQ listed QURE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of QURE?
-
Richard Porter | Chief Business & Scientific Officer
Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary
Chiara Elizabeth Russo | Senior Director of Investor Relations
Walid Abi-Saab | Chief Medical Officer
Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site -
How many employees does QURE have?
-
Number of QURE employees currently stands at 221. QURE operates from Paasheuvelweg 25, Amsterdam, NH 1105 BP, NL.
-
Link for QURE official website?
-
Official Website of QURE is: https://www.uniqure.com
-
How do I contact QURE?
-
QURE could be contacted at phone #31 20 240 6000 and can also be accessed through its website. QURE operates from Paasheuvelweg 25, Amsterdam, NH 1105 BP, NL.
-
How many shares of QURE are traded daily?
-
The average number of QURE shares traded daily for last 3 months was 2.18M.
-
What is the market cap of QURE currently?
-
The market value of QURE currently stands at $3B with its latest stock price at $43.2708